Form 13F-HR LANSDOWNE PARTNERS (UK) For: Mar 31 May 14, 2026 04:04PM
Form 13F-HR LANSDOWNE PARTNERS (UK) For: Dec 31 Feb 13, 2026 01:36PM
Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Sep 30 Nov 19, 2025 05:03PM
Form 13F-HR LANSDOWNE PARTNERS (UK) For: Sep 30 Nov 14, 2025 06:01AM
Form N-PX LANSDOWNE PARTNERS (UK) For: Jun 30 Aug 29, 2025 09:52AM
View Older Stories

Aug 14, 2025 06:03AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Jun 30
Jun 9, 2025 05:03AM IONQ Inc (IONQ) Announces Agreement to Acquire Oxford Ionics,
May 20, 2025 11:05AM Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Jun 30
May 20, 2025 10:51AM Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Mar 31
May 20, 2025 10:43AM Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Dec 31
May 15, 2025 01:04PM Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Dec 31
May 15, 2025 01:02PM Form 13F-HR/A LANSDOWNE PARTNERS (UK) For: Sep 30
May 14, 2025 03:06PM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Mar 31
Feb 13, 2025 01:45PM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Dec 31
Nov 13, 2024 05:00PM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Sep 30
Aug 28, 2024 04:39PM Form N-PX LANSDOWNE PARTNERS (UK) For: Jun 30
Aug 14, 2024 06:02AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Jun 30
May 14, 2024 10:23AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Mar 31
Apr 30, 2024 07:00AM Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
Mar 13, 2024 05:04AM Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda
Mar 11, 2024 07:00AM Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
Feb 14, 2024 06:00AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Dec 31
Feb 13, 2024 09:55PM Form SC 13G Soho House & Co Inc. Filed by: LANSDOWNE PARTNERS (UK) LLP
Jan 25, 2024 03:00AM Moa Reveals Data on Next-Generation Herbicides with New Modes of Action and Progress Towards Field Trials
Dec 18, 2023 07:00AM Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
Dec 18, 2023 07:00AM Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
Dec 1, 2023 09:16AM TechMet Receives further $50 Million Commitment From U.S. International Development Finance Corporation at COP28
Nov 29, 2023 04:00AM Former Bayer SVP Global Crop Protection Asset Management Hartmut van Lengerich appointed as Chairman of Moa Technology
Nov 27, 2023 06:02AM OQC launches OQC Toshiko, the world's first enterprise ready quantum platform
Nov 20, 2023 04:00AM Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides
Nov 14, 2023 06:02AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Sep 30
Oct 30, 2023 05:00AM Moa Technology wins World Economic Forum award for research tackling herbicide-resistant weeds that pose a global threat to food security
Sep 21, 2023 08:00AM Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Sep 21, 2023 08:00AM Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Aug 15, 2023 01:00AM TechMet closes $200m equity raise to further develop critical minerals operations
Aug 14, 2023 06:03AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Jun 30
Jul 24, 2023 07:00AM Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
Jun 20, 2023 07:00AM Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
May 25, 2023 07:00AM Cristian Massacesi, M.D., Appointed to Replay Board of Directors
May 18, 2023 08:00AM Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 15, 2023 06:23AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Mar 31
Feb 14, 2023 07:01AM KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
Feb 14, 2023 07:01AM KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
Feb 10, 2023 12:47PM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Dec 31
Feb 8, 2023 03:18PM Form SC 13G Membership Collective Filed by: LANSDOWNE PARTNERS (UK) LLP
Dec 14, 2022 07:00AM Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
Dec 14, 2022 07:00AM Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
Nov 28, 2022 07:00AM Replay receives $1.5 million grant for its hypoimmunogenic technology platform
Nov 28, 2022 07:00AM Replay receives $1.5 million grant for its hypoimmunogenic technology platform
Nov 21, 2022 07:00AM Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
Nov 21, 2022 07:00AM Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
Nov 10, 2022 09:10AM Form 13F-HR LANSDOWNE PARTNERS (UK) For: Sep 30
Nov 7, 2022 07:00AM Osler Diagnostics Raises $85 Million in Series C Financing
Nov 7, 2022 07:00AM Osler Diagnostics Raises $85 Million in Series C Financing
Oct 31, 2022 07:00AM Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
View Older Stories